Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  BioLargo, Inc.    BLGO

BIOLARGO, INC. (BLGO)
My previous session
Most popular
Delayed Quote. Delayed  - 01/17 10:27:54 am
0.234 USD   +4.93%
SummaryQuotesChartsNewsCompany 
News SummaryMost relevantAll newsOfficial PublicationsSector news

BioLargo, Inc. (OTCMKTS:BLGO) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

share with twitter share with LinkedIn share with facebook
share via e-mail
0
01/11/2019 | 04:58pm EST

BioLargo, Inc. (OTCMKTS:BLGO) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

The discussion set forth in Item 1.01 is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d)Exhibits.

Exhibit

Number

Exhibit Description

Form

File Date

10.1

Convertible Promissory Note issued to Vista Capital Investments LLC dated December 14, 2017

Form 8-K

12/22/2017

10.2

December 18, 2017, amendment to Promissory Note dated December 14, 2017 issued to Vista Capital Investments, LLC.

Form 8-K

12/22/2017

10.3

September 2018 Amendment to Promissory Note dated December 14, 2017 issued to Vista Capital Investments, LLC.

Form 8-K

9/18/2018

10.4

Convertible Promissory Note issued to Triton Funds LP dated October 12, 2018

Form 8-K

10/22/2018

10.5*

January 2019 Amendment to Promissory Note dated December 14, 2017, by and between BioLargo, Inc. and Vista Capital Investments, LLC.

10.6*

Convertible Promissory Note issued to Vista Capital Investments LLC dated January 7, 2019

* Filed hereto.

BIOLARGO, INC. Exhibit
EX-10.5 2 ex_132768.htm EXHIBIT 10.5 ex_132768.htm Exhibit 10.5   AMENDMENT  TO THE PROMISSORY NOTE DATED December 14,…
To view the full exhibit click here

About BioLargo, Inc. (OTCMKTS:BLGO)

BioLargo, Inc. is a provider of platform technologies. The Company’s products are used to eliminate contaminants that threaten the water, health and quality of life. Its technology has commercial applications within several industries. The Company focuses on four areas: water treatment; industrial odor control applications; commercial, household and personal care products (CHAPP), and advanced wound care. Its AOS Filter combines iodine, water filter materials and electrolysis within a water filter device. It generates oxidation potential in order to oxidize and breakdown or otherwise eliminate, soluble organic contaminant, which are found in contaminated water. Its CupriDyne formula is used to deliver iodine within products. The Isan System is an automated iodine dosing system, which features controlled measuring, flow control, dosing and iodine extraction and removal technology, as well as an automatic tracking system that delivers iodine in calibrated doses.

The post BioLargo, Inc. (OTCMKTS:BLGO) Files An 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant appeared first on Market Exclusive.

© Market Exclusive 2019, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BIOLARGO, INC.
01/11BIOLARGO, INC. : Creation of a Direct Financial Obligation or an Obligation unde..
AQ
2018BIOLARGO : BioLargos subsidiary Clyra Medical secures over $1 million in direct ..
AQ
2018BIOLARGO, INC. : Financial Statements and Exhibits (form 8-K)
AQ
2018BioLargo's subsidiary Clyra Medical secures over $1 million in direct investm..
GL
2018BIOLARGO : Management's Discussion and Analysis of Financial Condition and Resul..
AQ
2018BIOLARGO : s CEO Discusses Business Milestones and FDA Progress with Uptick News..
AQ
2018BIOLARGO : CEO Discusses Business Milestones and FDA Progress with Uptick Newswi..
AQ
2018BIOLARGO : Letter to Stockholders Details Companys Recent Milestones and Success..
AQ
2018BIOLARGO : Letter to Stockholders Details Company's Recent Milestones and Succes..
AQ
2018BIOLARGO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (fo..
AQ
More news
Chart BIOLARGO, INC.
Duration : Period :
BioLargo, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Dennis P. Calvert Chairman, President & Chief Executive Officer
Joseph L. Provenzano Secretary, Director & Vice President-Operations
Charles K. Dargan CFO & Principal Accounting Officer
Kenneth Reay Code Director & Chief Science Officer
Dennis E. Marshall Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOLARGO, INC.-6.89%0
SAUDI BASIC INDUSTRIES CORPORATION SJSC--.--%98 064
AIR LIQUIDE-4.15%50 834
SHIN-ETSU CHEMICAL CO LTD5.00%33 955
LYONDELLBASELL INDUSTRIES1.95%32 526
GIVAUDAN4.35%22 118